查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1658719

全球单株抗体 (mAb) 治疗市场按来源、应用/治疗领域、分销管道、地区、趋势分析、竞争格局、预测（2019-2031 年）

Monoclonal Antibody Therapeutics Market, By Source; By Application/Therapy Area; By Distribution Channel, By Region, Global Trend Analysis, Competitive Landscape & Forecast, 2019-2031
出版日期: | 出版商: Blueweave Consulting | 英文 512 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于慢性病发病率不断上升、生物製药研发项目投入不断增加以及 mAb 治疗应用不断扩大，全球单株抗体 (mAb) 治疗市场正在蓬勃发展。

预计 2024 年全球单株抗体 (mAb) 治疗市场规模将达 2,732 亿美元。预计到 2031 年将成长一倍以上，达到 5,593 亿美元，在 2025-2031 年预测期内的复合年增长率为 11.2%。癌症和心血管疾病等慢性疾病的增加正在推动对生技药品的需求，尤其是标靶治疗，例如单株抗体。患者和医疗保健提供者对 mAb 治疗效果的认识不断提高也是支持全球单株抗体 (mAb) 治疗市场的一个主要驱动因素。由免疫动物的细胞株或克隆产生的单株抗体已成为现代医学必不可少的物质。其针对特定疾病标记或病原体的能力巩固了其广泛的适用性。随着礼来公司的 bebtelovimab（已获得 FDA 紧急使用授权）等 mAb治疗方法的开发，COVID-19 疫情进一步加速了市场发展势头。 mAb疗法具有特异性、有效性和给药方便等优点，已导致许多产品的上市和核准，目前已有超过100种mAb核准。片段抗体、双特异性抗体和其他先进疗法等各领域的持续创新有望扩大治疗应用。此外，主要参与企业的策略性倡议继续推动全球单株抗体（mAb）治疗市场的扩张。

机会－扩大单株抗体的全球取得管道

单株抗体 (mAb) 彻底改变了癌症、自体免疫疾病和 COVID-19 和 HIV 等感染疾病的治疗方法，但其可及性仍然有限，全球 85% 的人口居住在中低收入国家，而 80% 的销售额集中在高所得地区。为了解决这一差距，IAVI和Wellcome等全球卫生组织已发出行动呼吁，敦促相关利益者提高对单株抗体拯救生命潜力的认识，扩大许可，降低生产成本，并开发永续取得的创新经营模式。融合瘤技术、电融合、基因改造动物和基于核酸的 mAb 的进步透过提高特异性、降低免疫抗原性和简化生产来提高生产力。这些创新可以实现更精确的治疗，并且副作用更少，针对癌症和其他有害细胞的特异性抗原。随着 mAb 市场的成长，提高可得性对于确保这些创新疗法公平分配和最大限度地发挥其在世界范围内的影响至关重要。

地缘政治紧张局势加剧对全球单株抗体 (mAb) 治疗市场的影响

不断加剧的地缘政治紧张局势可能会阻碍全球单株抗体（mAb）治疗市场的成长。潜在的干扰因素，包括贸易限制、关税提高、供应链脆弱性和法规环境波动，可能会阻碍 mAb 的生产和分销，从而可能增加成本并限制患者获得药物的机会。相反，这种紧张局势可能促使各国政府优先考虑卫生安全、扩大国内生物製药生产能力、加强本土生产、减少对进口的依赖，并鼓励供应链的弹性和替代製造策略的创新。因此，虽然地缘政治不确定性带来了重大挑战，但也可能刺激进步并再形成全球 mAb 治疗市场的未来轨迹。

北美引领全球单株抗体（mAb）治疗市场

北美引领全球单株抗体（mAb）治疗市场，这主要是由于高昂的医疗成本，尤其是美国。儘管美国的医疗保健支出远远超过其他国家，但这种支出并没有转化为健康状况的相应改善。高价格和服务利用率导緻美国医疗费用飙升。同时，由于创新研究、技术进步和医疗服务需求的不断增长，加拿大的医疗保健产业正在呈现强劲成长。加拿大医疗保健格局的动态发展进一步增强了北美市场的整体主导地位和 mAb 治疗领域的成长潜力。为体现这一市场动态，2022 年 1 月，葛兰素史克和 Vir Biotechnology 与美国政府签署了一项重要协议，以购买额外的 sotrovimab（一种获批用于早期治疗 COVID-19 的 mAb）。

本报告对全球单株抗体（mAb）治疗市场进行了深入分析，并提供了有关成长潜力和未来趋势的资讯。它还分析了市场的成长动力、挑战和竞争动态。

目录

第一章 调查框架

第 2 章执行摘要

第 3市场考察。

  • 最终用户价值链分析
  • DROC 分析
    • 成长动力
      • 慢性病增加
      • 增加对单株抗体研发专案的投资
      • 扩充应用
    • 限制因素
      • mAb治疗成本高
      • 严格的监管要求
    • 机会
      • 新型 mAb治疗方法的开发
      • 个人化医疗的采用日益增多
    • 任务
      • 生物相似药的竞争
      • 潜在的副作用
  • 科技进步/最新发展
  • 法规结构
  • 波特五力分析

第 4 章。

5. 全球单株抗体 (mAb) 治疗市场：定价分析

6. 全球单株抗体 (mAb) 治疗市场：区域分析

  • 全球单株抗体 (mAb) 治疗市场，区域分析（2024 年）
  • 全球单株抗体 (mAb) 治疗市场吸引力分析（2024-2031 年）

7. 全球单株抗体 (mAb) 治疗市场概述

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
      • 人类
      • 人性化
      • 嵌合体
      • 鼠
    • 按应用/治疗领域
      • 瘤
      • 自体免疫疾病
      • 感染疾病
      • 血液系统疾病
      • 心血管疾病
      • 其他的
    • 按分销管道
      • 医院
      • 零售药局
      • 网路药局
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区
      • 拉丁美洲
      • 中东和非洲

8. 北美单株抗体 (mAb) 治疗市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
    • 按应用
    • 按分销管道
    • 按国家
      • 美国
      • 加拿大

9. 欧洲单株抗体 (mAb) 治疗市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
    • 按应用
    • 按分销管道
    • 按国家
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 欧洲其他地区

10. 亚太地区单株抗体 (mAb) 治疗市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
    • 按应用
    • 按分销管道
    • 按国家
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

11. 拉丁美洲单株抗体 (mAb) 治疗市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
    • 按应用
    • 按分销管道
    • 按国家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲国家

12. 中东和非洲单株抗体 (mAb) 治疗市场

  • 市场规模及预测（2019-2031）
    • 金额
  • 市场占有率和预测
    • 按产地
    • 按应用
    • 按分销管道
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东和非洲地区

第十三章 竞争格局

  • 主要企业及其产品列表
  • 全球单株抗体 (mAb) 治疗市场占有率分析（2024 年）
  • 竞争性基准化分析：根据业务参数
  • 重大策略发展（合併、收购、联盟）

14. 地缘政治紧张局势加剧对全球单株抗体 (mAb) 治疗市场的影响

第 15 章 公司简介（公司概况、财务矩阵、竞争格局、关键人员、主要竞争对手、联繫、策略展望、SWOT 分析）

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen Inc
  • Bristol Myers Squibb Company (US)
  • Merck & Co Inc
  • AstraZeneca plc
  • Sanofi
  • Bayer AG
  • Eli Lilly and Company
  • Thermo Fisher Scientific Inc
  • 其他知名公司

第十六章 关键策略建议

第十七章调查方法

简介目录
Product Code: BWC25080

Global Monoclonal Antibody (mAb) Therapeutics Market Zooming 2X to Touch USD 560 Billion by 2031

Global Monoclonal Antibody (mAb) Therapeutics Market is flourishing because of the rising incidence of chronic diseases, increasing investments in biopharma R&D programs, and the expanding therapeutic applications of mAbs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated Global Monoclonal Antibody (mAb) Therapeutics Market size at USD 273.2 billion in 2024. During the forecast period between 2025 and 2031, BlueWeave expects Global Monoclonal Antibody (mAb) Therapeutics Market size to more than doubles at a robust CAGR of 11.2% reaching a value of USD 559.3 billion by 2031. The increasing prevalence of chronic diseases, including cancer and cardiovascular conditions, fuels demand for biologics like mAbs, particularly for targeted therapies. Growing awareness among both patients and healthcare providers regarding the efficacy of mAb treatments are also major driving forces behind the Global Monoclonal Antibody (mAb) Therapeutics Market. mAbs, generated from cell lines or clones derived from immunized animals, have become indispensable in modern medicine. Their ability to target specific disease markers and pathogens underpins their broad applicability. The COVID-19 pandemic, with the development of mAb treatments like Eli Lilly's bebtelovimab (which received FDA emergency use authorization), further accelerated the market momentum. The advantages of mAb therapies, including their specificity, effectiveness, and convenient delivery methods, have resulted in numerous product launches and approvals, with over 100 mAbs currently holding FDA approval. Ongoing innovations in various areas, such as antibody fragments, bispecific antibodies, and other advanced therapies, promises to broaden their therapeutic applications. Furthermore, strategic initiatives undertaken by key market players continue to propel the expansion of Global Monoclonal Antibody (mAb) Therapeutics Market.

Opportunity - Expanding Global Access to Monoclonal Antibodies

Monoclonal antibodies (mAbs) have revolutionized the treatment of cancers, autoimmune diseases, and infectious diseases like COVID-19 and HIV, but access remains limited, with 80% of sales concentrated in high-income regions while 85% of the global population resides in low- and middle-income countries. To address this gap, global health organizations such as IAVI and Wellcome have issued a call to action, urging stakeholders to raise awareness of mAbs' life-saving potential, expand their licensure, reduce production costs, and create innovative business models for sustainable access. Advancements in hybridoma technology, electrofusion, transgenic animals, and nucleic acid-based mAbs are enhancing production by improving specificity, reducing immunogenicity, and simplifying manufacturing. These innovations enable more precise treatments with fewer side effects, targeting specific antigens on cancer and other unwanted cells. As the mAb market grows, increasing accessibility will be crucial in ensuring these transformative therapies are equitably distributed, maximizing their global impact.

Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

Intensifying geopolitical tensions could disrupt the growth of Global Monoclonal Antibody (mAb) Therapeutics Market. Potential disruptions, including trade restrictions, increased tariffs, supply chain vulnerabilities, and fluctuating regulatory environments, could impede mAb production and distribution, potentially increasing costs and restricting patient access, while also negatively impacting international pharmaceutical collaborations and investments in biologic drug development. Conversely, these tensions may stimulate increased government focus on healthcare security and the development of domestic biopharmaceutical manufacturing capacity, potentially bolstering regional production, reducing import reliance, and fostering innovation in supply chain resilience and alternative manufacturing strategies. Thus, while geopolitical uncertainties pose significant challenges, they may also inadvertently drive advancements and reshape the future trajectory of Global mAb Therapeutics Market.

North America Leads Global Monoclonal Antibody (mAb) Therapeutics Market

North America commands the leading position in Global Monoclonal Antibody (mAb) Therapeutics Market, primarily fueled by substantial healthcare expenditures, particularly in the United States. While United States healthcare spending significantly outpaces that of other nations, this expenditure does not consistently translate into proportionally improved health outcomes. High service prices and utilization rates contribute to the escalating costs within the United States system. Concurrently, Canada's medical sector is experiencing robust growth, driven by innovative research, technological advancements, and increasing demand for healthcare services. This dynamic evolution of the Canadian healthcare landscape further strengthens North America's overall market dominance and growth potential in the mAb therapeutics arena. Illustrating this market activity, in January 2022, GSK and Vir Biotechnology secured a significant agreement with the United States government for the purchase of additional supplies of sotrovimab, a mAb authorized for early treatment of COVID-19.

Competitive Landscape

Major companies in Global Monoclonal Antibody (mAb) Therapeutics Market include F. Hoffmann-La Roche Ltd, Novartis AG, Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Amgen Inc, Bristol Myers Squibb Company (US), Merck & Co Inc, AstraZeneca plc, Sanofi, Bayer AG, Eli Lilly and Company, and Thermo Fisher Scientific Inc. The presence of high number of companies intensify the market competition as they compete to gain a significant market share. These companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches to further enhance their market share.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and Global Monoclonal Antibody (mAb) Therapeutics Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Monoclonal Antibody (mAb) Therapeutics Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Monoclonal Antibody (mAb) Therapeutics Market Insights

  • 3.1. End User Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing Prevalence of Chronic Diseases
      • 3.2.1.2. Growing Investments in (mAb) R&D Programs
      • 3.2.1.3. Expanding Applications
    • 3.2.2. Restraints
      • 3.2.2.1. High Cost of (mAb) Therapies
      • 3.2.2.2. Stringent Regulatory Requirements
    • 3.2.3. Opportunities
      • 3.2.3.1. Developing Novel (mAb) Therapies
      • 3.2.3.2. Growing Adoption of Personalized Medicines
    • 3.2.4. Challenges
      • 3.2.4.1. Competitions from Biosimilars
      • 3.2.4.2. Potential Side Effects
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Monoclonal Antibody (mAb) Therapeutics Market: Marketing Strategies

5. Global Monoclonal Antibody (mAb) Therapeutics Market: Pricing Analysis

6. Global Monoclonal Antibody (mAb) Therapeutics Market: Geography Analysis

  • 6.1. Global Monoclonal Antibody (mAb) Therapeutics Market, Geographical Analysis, 2024
  • 6.2. Global Monoclonal Antibody (mAb) Therapeutics, Market Attractiveness Analysis, 2024-2031

7. Global Monoclonal Antibody (mAb) Therapeutics Market Overview

  • 7.1. Market Size & Forecast, 2019-2031
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
      • 7.2.1.1. Human
      • 7.2.1.2. Humanized
      • 7.2.1.3. Chimeric
      • 7.2.1.4. Murine
    • 7.2.2. By Application/Therapy Area
      • 7.2.2.1. Oncology
      • 7.2.2.2. Autoimmune Diseases
      • 7.2.2.3. Infectious Diseases
      • 7.2.2.4. Hematological Disorders
      • 7.2.2.5. Cardiovascular Diseases
      • 7.2.2.6. Others
    • 7.2.3. By Distribution Channel
      • 7.2.3.1. Hospitals
      • 7.2.3.2. Retail Pharmacies
      • 7.2.3.3. Online Pharmacies
    • 7.2.4. By Region
      • 7.2.4.1. North America
      • 7.2.4.2. Europe
      • 7.2.4.3. Asia Pacific (APAC)
      • 7.2.4.4. Latin America (LATAM)
      • 7.2.4.5. Middle East and Africa (MEA)

8. North America Monoclonal Antibody (mAb) Therapeutics Market

  • 8.1. Market Size & Forecast, 2019-2031
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Application
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.1.1. By Source
      • 8.2.4.1.2. By Application
      • 8.2.4.1.3. By Distribution Channel
      • 8.2.4.2. Canada
      • 8.2.4.2.1. By Source
      • 8.2.4.2.2. By Application
      • 8.2.4.2.3. By Distribution Channel

9. Europe Monoclonal Antibody (mAb) Therapeutics Market

  • 9.1. Market Size & Forecast, 2019-2031
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Application
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
      • 9.2.4.1. Germany
      • 9.2.4.1.1. By Source
      • 9.2.4.1.2. By Application
      • 9.2.4.1.3. By Distribution Channel
      • 9.2.4.2. United Kingdom
      • 9.2.4.2.1. By Source
      • 9.2.4.2.2. By Application
      • 9.2.4.2.3. By Distribution Channel
      • 9.2.4.3. Italy
      • 9.2.4.3.1. By Source
      • 9.2.4.3.2. By Application
      • 9.2.4.3.3. By Distribution Channel
      • 9.2.4.4. France
      • 9.2.4.4.1. By Source
      • 9.2.4.4.2. By Application
      • 9.2.4.4.3. By Distribution Channel
      • 9.2.4.5. Spain
      • 9.2.4.5.1. By Source
      • 9.2.4.5.2. By Application
      • 9.2.4.5.3. By Distribution Channel
      • 9.2.4.6. Belgium
      • 9.2.4.6.1. By Source
      • 9.2.4.6.2. By Application
      • 9.2.4.6.3. By Distribution Channel
      • 9.2.4.7. Russia
      • 9.2.4.7.1. By Source
      • 9.2.4.7.2. By Application
      • 9.2.4.7.3. By Distribution Channel
      • 9.2.4.8. The Netherlands
      • 9.2.4.8.1. By Source
      • 9.2.4.8.2. By Application
      • 9.2.4.8.3. By Distribution Channel
      • 9.2.4.9. Rest of Europe
      • 9.2.4.9.1. By Source
      • 9.2.4.9.2. By Application
      • 9.2.4.9.3. By Distribution Channel

10. Asia Pacific Monoclonal Antibody (mAb) Therapeutics Market

  • 10.1. Market Size & Forecast, 2019-2031
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Application
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
      • 10.2.4.1. China
      • 10.2.4.1.1. By Source
      • 10.2.4.1.2. By Application
      • 10.2.4.1.3. By Distribution Channel
      • 10.2.4.2. India
      • 10.2.4.2.1. By Source
      • 10.2.4.2.2. By Application
      • 10.2.4.2.3. By Distribution Channel
      • 10.2.4.3. Japan
      • 10.2.4.3.1. By Source
      • 10.2.4.3.2. By Application
      • 10.2.4.3.3. By Distribution Channel
      • 10.2.4.4. South Korea
      • 10.2.4.4.1. By Source
      • 10.2.4.4.2. By Application
      • 10.2.4.4.3. By Distribution Channel
      • 10.2.4.5. Australia and New Zealand
      • 10.2.4.5.1. By Source
      • 10.2.4.5.2. By Application
      • 10.2.4.5.3. By Distribution Channel
      • 10.2.4.6. Indonesia
      • 10.2.4.6.1. By Source
      • 10.2.4.6.2. By Application
      • 10.2.4.6.3. By Distribution Channel
      • 10.2.4.7. Malaysia
      • 10.2.4.7.1. By Source
      • 10.2.4.7.2. By Application
      • 10.2.4.7.3. By Distribution Channel
      • 10.2.4.8. Singapore
      • 10.2.4.8.1. By Source
      • 10.2.4.8.2. By Application
      • 10.2.4.8.3. By Distribution Channel
      • 10.2.4.9. Vietnam
      • 10.2.4.9.1. By Source
      • 10.2.4.9.2. By Application
      • 10.2.4.9.3. By Distribution Channel
      • 10.2.4.10. Rest of APAC
      • 10.2.4.10.1. By Source
      • 10.2.4.10.2. By Application
      • 10.2.4.10.3. By Distribution Channel

11. Latin America Monoclonal Antibody (mAb) Therapeutics Market

  • 11.1. Market Size & Forecast, 2019-2031
    • 11.1.1. By Value (USD Billion)
  • 11.2. Market Share & Forecast
    • 11.2.1. By Source
    • 11.2.2. By Application
    • 11.2.3. By Distribution Channel
    • 11.2.4. By Country
      • 11.2.4.1. Brazil
      • 11.2.4.1.1. By Source
      • 11.2.4.1.2. By Application
      • 11.2.4.1.3. By Distribution Channel
      • 11.2.4.2. Mexico
      • 11.2.4.2.1. By Source
      • 11.2.4.2.2. By Application
      • 11.2.4.2.3. By Distribution Channel
      • 11.2.4.3. Argentina
      • 11.2.4.3.1. By Source
      • 11.2.4.3.2. By Application
      • 11.2.4.3.3. By Distribution Channel
      • 11.2.4.4. Peru
      • 11.2.4.4.1. By Source
      • 11.2.4.4.2. By Application
      • 11.2.4.4.3. By Distribution Channel
      • 11.2.4.5. Rest of LATAM
      • 11.2.4.5.1. By Source
      • 11.2.4.5.2. By Application
      • 11.2.4.5.3. By Distribution Channel

12. Middle East and Africa Monoclonal Antibody (mAb) Therapeutics Market

  • 12.1. Market Size & Forecast, 2019-2031
    • 12.1.1. By Value (USD Billion)
  • 12.2. Market Share & Forecast
    • 12.2.1. By Source
    • 12.2.2. By Application
    • 12.2.3. By Distribution Channel
    • 12.2.4. By Country
      • 12.2.4.1. Saudi Arabia
      • 12.2.4.1.1. By Source
      • 12.2.4.1.2. By Application
      • 12.2.4.1.3. By Distribution Channel
      • 12.2.4.2. UAE
      • 12.2.4.2.1. By Source
      • 12.2.4.2.2. By Application
      • 12.2.4.2.3. By Distribution Channel
      • 12.2.4.3. Qatar
      • 12.2.4.3.1. By Source
      • 12.2.4.3.2. By Application
      • 12.2.4.3.3. By Distribution Channel
      • 12.2.4.4. Kuwait
      • 12.2.4.4.1. By Source
      • 12.2.4.4.2. By Application
      • 12.2.4.4.3. By Distribution Channel
      • 12.2.4.5. South Africa
      • 12.2.4.5.1. By Source
      • 12.2.4.5.2. By Application
      • 12.2.4.5.3. By Distribution Channel
      • 12.2.4.6. Nigeria
      • 12.2.4.6.1. By Source
      • 12.2.4.6.2. By Application
      • 12.2.4.6.3. By Distribution Channel
      • 12.2.4.7. Algeria
      • 12.2.4.7.1. By Source
      • 12.2.4.7.2. By Application
      • 12.2.4.7.3. By Distribution Channel
      • 12.2.4.8. Rest of MEA
      • 12.2.4.8.1. By Source
      • 12.2.4.8.2. By Application
      • 12.2.4.8.3. By Distribution Channel

13. Competitive Landscape

  • 13.1. List of Key Players and Their Offerings
  • 13.2. Global Monoclonal Antibody (mAb) Therapeutics Company Market Share Analysis, 2024
  • 13.3. Competitive Benchmarking, By Operating Parameters
  • 13.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships)

14. Impact of Escalating Geopolitical Tensions on Global Monoclonal Antibody (mAb) Therapeutics Market

15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 15.1. F. Hoffmann-La Roche Ltd
  • 15.2. Novartis AG
  • 15.3. Johnson & Johnson Services, Inc.
  • 15.4. GlaxoSmithKline plc
  • 15.5. Merck & Co., Inc.
  • 15.6. Amgen Inc
  • 15.7. Bristol Myers Squibb Company (US)
  • 15.8. Merck & Co Inc
  • 15.9. AstraZeneca plc
  • 15.10. Sanofi
  • 15.11. Bayer AG
  • 15.12. Eli Lilly and Company
  • 15.13. Thermo Fisher Scientific Inc
  • 15.14. Other Prominent Players

16. Key Strategic Recommendations

17. Research Methodology

  • 17.1. Qualitative Research
    • 17.1.1. Primary & Secondary Research
  • 17.2. Quantitative Research
  • 17.3. Market Breakdown & Data Triangulation
    • 17.3.1. Secondary Research
    • 17.3.2. Primary Research
  • 17.4. Breakdown of Primary Research Respondents, By Region
  • 17.5. Assumptions & Limitations

*Financial information of non-listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable